FDA stamps approval on GSK cancer drug Votrient

GlaxoSmithKline ($GSK) has scored a new U.S. approval for Votrient, making the drug the first new treatment for cancers called soft tissue sarcomas in decades. The FDA nod follows a study that showed…
Read the full story: News